About
Dr. Elliot Parks is a fund manager with over 25 years of intimate knowledge and professional experience in biotechnology start-ups, large pharmaceutical companies, and academic research institutions. His corporate and institutional venture capital successes have leveraged his experience commercializing biomedical products in pharmaceutical and biotechnology setting. He serves on the TransOral Board of Directors. Prior to joining Hamilton, Dr. Parks was Managing Director of Ventana Capital Management, raising and managing two venture funds and successfully overseeing the firm’s life science practice. While at Ventana, he served on several boards of directors and, among the accomplishments, led the recapitalization and venture syndication of Idun Pharmaceuticals, a San Diego biopharmaceutical company recently acquired by Pfizer for close to $300 million. Dr. Parks served as President and CEO of Myelos Neurosciences Corp, a biopharmaceutical company developing a new family of therapeuti
Position in the VCSift Database
- • 266 investors hold the President and CEO role in VCSift. D.Elliot Parks is one of them.
- • 70 investors are based in Honolulu, Hawaii, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Honolulu, US
Contact Information
Find more investors like D.Elliot
Search Investors